The 2020 ALK-positive Lung Cancer Research Award Program is now closed for application submissions.
ALK-positive lung cancer is a type of non-small cell lung cancer (NSCLC) in which the ALK gene is fused with, or attached to, a part of another gene. The fused gene produces a unique ALK protein that promotes abnormal, unchecked cell growth. About 5% of lung cancer patients have the ALK mutation. While there are currently five FDA-approved targeted therapies to treat ALK-positive lung cancer, the cancer inevitably recurs because the cells become resistant to the effects of the targeted therapies. Thus, there is a huge unmet need for additional treatment options for ALK-positive lung cancer patients.
ALK Positive—a group of 1,900+ ALK-positive patients and their caregivers in 42+ countries who are raising significant funds for research—and LUNGevity Foundation have partnered to support high-impact research that seeks to transform the future for patients affected by ALK-positive non-small cell lung cancer. This is the first group of ALK-positive patients to directly influence the direction of research that will, one day, save their lives.
Funded projects are expected to have a direct impact on the outcomes of patients with ALK-positive lung cancer, but innovative proposals that address other unmet needs in the ALK-positive lung cancer space are also invited for submission. Applicants are encouraged to propose projects that utilize the resources of the ALK Positive members, which include their available histories, opinions, tissues, bodily fluids, and any other aspects of their condition.
This award is open to researchers at both U.S. and international institutions. Note that, at the time of application, international applicants must name a co-investigator at a U.S. institution. All research funds will be disbursed through a U.S. institution.
The award program has two mechanisms:
- Transformational Award
- A maximum of $500,000 over two years
- Examples of research include, but are not restricted to, correlative studies with patient samples
- Clinical Trial Innovation Award
- A maximum of $750,000 over two years
- Research includes a clinical trial
Six-month milestones must be met.
An applicant may submit no more than two applications for this award.
2020 ALK-Positive lung cancer Research Award
- $125,000 in each of four 6-month periods
- Award may be for maximum of $500,000 over two years
Clinical Innovation Award
- $187,500 in each of four 6-month periods
- Award may be for maximum of $750,000 over two years
6-month milestones must be met
LUNGevity uses a two-step application process:
1. A letter of intent (LOI), with a brief overview of the proposed project and biographical information
2. A full application with an extended narrative about the project, as well as supporting information and documentation. (Because there are a limited number of awards, only a subset of applicants is invited to submit a full application after the LOI review is completed.)
Reviewers are drawn from the LUNGevity Scientific Advisory Board and other ALK experts.
Awardees have progress and financial reporting obligations during the award term.
Complete instructions and award details are included in the ALK-positive Lung Cancer Research Award Request for Applications.
LOIs and full applications must be submitted electronically via proposalCENTRAL.
2020 ALK-Positive lung cancer research award timeline
|LOI(s) due:||by February 14, 2020 (11:50 pm EST)|
|Full application invitation:||no earlier than Monday, March 23, 2020|
|Full application due (by invitation only):||by Friday, May 1, 2020 (11:59 pm EST)|
|Award announcement:||Summer 2020|
|Anticipated initial funding disbursement:||Fall 2020|